Evidence map›Paper›PMID 36158103›Full record

ArticleHeliyon2022

Machine learning-based prognosis signature for survival prediction of patients with clear cell renal cell carcinoma.

Siteng Chen, Tuanjie Guo, Encheng Zhang, Tao Wang, Guangliang Jiang, Yishuo Wu, Xiang Wang, Rong Na, Ning Zhang

Abstract read
In one paragraph

Article in Heliyon, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Siteng ChenDepartment of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Tuanjie GuoDepartment of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Encheng ZhangDepartment of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Tao WangDepartment of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Guangliang JiangDepartment of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yishuo WuDepartment of Urology, Huashan Hospital, Fudan University, Shanghai, China.
Xiang WangDepartment of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Rong NaDepartment of Surgery, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China.
Ning ZhangDepartment of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The sole clinicopathological characteristic is not enough for the prediction of survival of patients with clear cell renal cell carcinoma (ccRCC). However, the survival prediction model constructed by machine learning technology for patients with ccRCC using clinicopathological features is rarely reported yet. In this study, a total of 5878 patients diagnosed as ccRCC from four independent patient cohorts were recruited. The least absolute shrinkage and selection operator analysis was implemented to identify optimal clinicopathological characteristics and calculate each coefficient to construct the prognosis model. In addition, weighted gene co-expression network and gene enrichment analysis associated with risk score were also carried out. Three clinicopathologic features were selected for the construction of the prognosis risk score model as the prognostic factors of ccRCC, including tumor size, tumor grade, and tumor stage. In the CPTAC (Clinical Proteomic Tumor Analysis Consortium) cohort, the General cohort, the SEER (Surveillance, Epidemiology, and End Results) cohort, and the Huashan cohort, patients with high-risk score had worse clinical outcomes than patients with low-risk score (hazard ratio 5.15, 4.64, 3.96, and 5.15, respectively). Further functional enrichment analysis demonstrated that our machine learning-based risk score was significantly connected with some cell proliferation-related pathways, consisting of DNA repair, cell division, and cell cycle. In summary, we developed and validated a machine learning-based prognosis prediction model, which might contribute to clinical decision-making for patients with ccRCC.

Indexed as

Clear cell renal cell carcinomaClinicopathologyMachine learningMulti-center studyPrognosis

Identifiers

PMID36158103
PMCPMC9489730

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.